Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 22:22 | 2026-06-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer | OPT+S | $227.06 | 5,000 | $1,135,316 | 41,382 |
| 2026-06-02 22:05 | 2026-06-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer | SELL | $6.06 | 16,667 | $100,982 | 1,176,506 |
| 2026-06-02 22:18 | 2026-06-01 | HYPD | HYPERION DEFI, INC. | Jung Hyunsu | Director, Officer | BUY | $3.70 | 8,000 | $29,580 | 1,385,676 |
| 2026-06-02 20:30 | 2026-05-29 | CNTB | Connect Biopharma Holdings Ltd | Huang James | Director | BUY | $2.48 | 150,000 | $371,610 | 13,310,000 |
| 2026-06-02 20:31 | 2026-05-29 | ANTX | AN2 Therapeutics, Inc. | Williams Sarah Joanne | Officer | SELL | $4.43 | 265 | $1,174 | 66,583 |
| 2026-06-02 20:32 | 2026-05-26 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | SELL | $575.96 | 1,500 | $863,947 | 43,153 |
| 2026-06-02 20:33 | 2026-06-01 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $547.87 | 10,000 | $5,478,663 | 18,876 |
| 2026-06-02 20:33 | 2026-06-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $547.91 | 9,500 | $5,205,104 | 40,513 |
| 2026-06-02 20:04 | 2026-05-29 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen | Officer | SELL | $450.00 | 1,974 | $888,300 | 22,760 |
| 2026-06-02 13:00 | 2026-06-01 | MAIA | MAIA Biotechnology, Inc. | Gryaznov Sergei | Officer | BUY | $1.35 | 2,000 | $2,690 | 46,511 |
| 2026-06-02 13:01 | 2026-06-01 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | BUY | $1.34 | 75,000 | $100,200 | 1,519,178 |
| 2026-06-02 13:02 | 2026-06-01 | MAIA | MAIA Biotechnology, Inc. | Vitoc Vlad | Director, Officer, 10% owner | BUY | $1.39 | 72,700 | $100,886 | 976,121 |
| 2026-06-02 11:00 | 2026-05-29 | KRRO | Korro Bio, Inc. | Aiyar Ram | Director, Officer | SELL | $12.98 | 15,152 | $196,673 | 74,848 |
| 2026-06-01 20:10 | 2026-05-29 | ASND | Ascendis Pharma A/S | SMITH SCOTT THOMAS | Officer | BUY | $223.32 | 250 | $55,830 | 4,267 |
| 2026-06-01 20:05 | 2026-05-28 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer | OPT+S | $16.00 | 679 | $10,864 | 47,122 |
| 2026-06-01 20:25 | 2026-05-28 | PGEN | PRECIGEN, INC. | Sabzevari Helen | Officer | SELL | $4.36 | 119,250 | $519,930 | 3,768,872 |
| 2026-06-01 20:06 | 2026-05-28 | JAZZ | Jazz Pharmaceuticals plc | Pearce Samantha | Officer | OPT+S | $235.41 | 6,907 | $1,625,977 | 50,272 |
| 2026-06-01 20:09 | 2026-05-28 | JAZZ | Jazz Pharmaceuticals plc | Patil Neena M | Officer | SELL | $236.97 | 1,192 | $282,468 | 52,626 |
| 2026-06-01 20:11 | 2026-05-29 | ASND | Ascendis Pharma A/S | BIENAIME JEAN JACQUES | Director | BUY | $223.12 | 500 | $111,562 | 900 |
| 2026-06-01 20:10 | 2026-05-28 | AIMD | Ainos, Inc. | chiang yao-chung | Director | BUY | $2.30 | 250 | $575 | 5,779 |
| 2026-06-02 01:13 | 2026-05-28 | QTTB | Q32 Bio Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | BUY | $8.00 | 1,875,000 | $15,000,000 | 625,000 |
| 2026-06-02 01:15 | 2026-05-28 | QTTB | Q32 Bio Inc. | Xu Diyong | Director, 10% owner | BUY | $8.00 | 1,875,000 | $15,000,000 | 625,000 |
| 2026-06-01 23:59 | 2026-05-28 | EVMN | Evommune, Inc. | Carver Kyle | Officer | OPT+S | $22.84 | 18,175 | $415,117 | 59,335 |
| 2026-06-02 00:00 | 2026-05-28 | EVMN | Evommune, Inc. | Moss Gregory S. | Officer | OPT+S | $22.83 | 14,223 | $324,711 | 60,835 |
| 2026-06-01 23:49 | 2026-06-01 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Soergel David | Officer | SELL | $495.74 | 1,042 | $516,561 | 10,033 |
| 2026-06-01 23:23 | 2026-06-01 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Officer | SELL | $25.77 | 2,562 | $66,024 | 39,581 |
| 2026-06-01 23:26 | 2026-06-01 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | OPT+S | $41.67 | 9,000 | $375,044 | 77,389 |
| 2026-06-01 23:11 | 2026-06-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer | SELL | $23.77 | 4,653 | $110,602 | 105,689 |
| 2026-06-01 22:51 | 2026-06-01 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $74.08 | 15,000 | $1,111,200 | 58,555 |
| 2026-06-01 22:54 | 2026-06-01 | CYTK | CYTOKINETICS INC | Kaye Edward M. MD | Director | SELL | $76.09 | 2,933 | $223,172 | 10,283 |
| 2026-06-01 22:49 | 2026-06-01 | CYTK | CYTOKINETICS INC | PARSHALL B LYNNE | Director | SELL | $74.08 | 5,000 | $370,400 | 15,784 |
| 2026-06-01 22:31 | 2026-05-29 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Director | OPT+S | $99.64 | 9,000 | $896,760 | 7,825 |
| 2026-06-01 22:08 | 2026-06-01 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Officer | SELL | $13.16 | 4,170 | $54,862 | 139,372 |
| 2026-06-01 21:35 | 2026-05-28 | KRRO | Korro Bio, Inc. | FORMELA JEAN FRANCOIS | Director | SELL | $13.95 | 2,860 | $39,897 | 194,655 |
| 2026-06-01 21:20 | 2026-06-01 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | 10% owner | SELL | $20.02 | 25,000 | $500,543 | 130,142 |
| 2026-06-01 21:21 | 2026-06-01 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian BioPharma Inc | 10% owner | SELL | $20.02 | 25,000 | $500,543 | 130,142 |
| 2026-06-01 20:55 | 2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Officer | BUY | $2.57 | 1,829 | $4,701 | 9,840 |
| 2026-06-01 20:56 | 2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Officer | BUY | $2.57 | 1,582 | $4,066 | 9,176 |
| 2026-06-01 20:58 | 2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | Director, Officer | BUY | $2.57 | 2,129 | $5,472 | 9,970 |
| 2026-06-01 20:59 | 2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | SKIBSTED RUSSELL | Officer | BUY | $2.57 | 2,292 | $5,890 | 10,758 |
| 2026-06-01 21:01 | 2026-05-29 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Director, Officer | BUY | $2.57 | 1,786 | $4,590 | 17,131 |
| 2026-06-01 20:26 | 2026-05-28 | PGEN | PRECIGEN, INC. | Lehr Donald P. | Officer | SELL | $4.36 | 29,131 | $127,011 | 755,461 |
| 2026-06-01 20:27 | 2026-05-28 | PGEN | PRECIGEN, INC. | Shah Rutul R | Officer | SELL | $4.36 | 42,703 | $186,185 | 497,751 |
| 2026-06-01 20:28 | 2026-05-28 | PGEN | PRECIGEN, INC. | Tennant Phil | Officer | SELL | $4.36 | 30,272 | $131,986 | 139,369 |
| 2026-06-01 20:29 | 2026-05-28 | PGEN | PRECIGEN, INC. | Thomasian Harry Jr. | Officer | SELL | $4.36 | 41,884 | $182,614 | 554,535 |
| 2026-06-01 20:30 | 2026-05-28 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | OPT+S | $107.84 | 5,500 | $593,101 | 59,634 |
| 2026-06-01 20:31 | 2026-05-29 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $553.83 | 9,500 | $5,261,365 | 40,513 |
| 2026-06-01 20:31 | 2026-05-28 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $107.80 | 5,500 | $592,923 | 58,117 |
| 2026-06-01 11:33 | 2026-05-29 | CMMB | Chemomab Therapeutics Ltd. | Mor George Adi | Director, Officer | BUY | $2.07 | 9,804 | $20,246 | 139,131 |
| 2026-05-29 20:05 | 2026-05-27 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $26.78 | 33,800 | $905,225 | 229,918 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.